安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- AstraZeneca | Cafepharma Message Boards | Pharma Sales, Device Sales . . .
Anonymous board for AstraZeneca
- AstraZeneca | Cafepharma
AstraZeneca has entered an agreement with China-based CSPC Pharmaceuticals to advance drug development programs targeting obesity and type 2 diabetes The deal covers eight programs, including one clinical-ready candidate, and provides AstraZeneca with access to CSPC’s AI-enabled peptide drug discovery platform and a proprietary once-monthly injectable formulation technology
- Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Anonymous discussion boards for pharmaceutical sales, medical device sales, lab diagnostics sales
- Cafepharma News
Latest news and updates on pharmaceutical and medical sales, including breakthrough treatments and industry trends
- January 14 2026 - JPM26: AstraZenecas $80B revenue target very much . . .
Confidence is on full display at JPM, as companies talk up revenue targets, pipeline momentum, and dealmaking strength—tempered by ongoing regulatory and pricing realities JPM26: AstraZeneca's $80B revenue target 'very much within reach,' CFO saysAstraZeneca boardAbbVie, Amgen, Lilly lead calls for FDA to update post-approval change rules
- July 24 2025 - AstraZeneca drug acquired in Alexion deal succeeds in . . .
AstraZeneca drug acquired in Alexion deal succeeds in autoimmune disease trialAstraZeneca boardPharma giant Roche sees income soar in first halfRoche boardNovartis to pay Matchpoint up to $1 billion to develop anti-inflammatory therapiesNovartis boardHow Bristol Myers Squibb uses AI to validate drugs before they’re even in the lab
- February 10 2026 - AstraZeneca sets sights on 25+ blockbusters by 2030 . . .
Biopharma headlines today reflect both long-term ambition and near-term rivalry AstraZeneca is mapping out an $80B growth path built on blockbuster expansion, while Novo Nordisk’s patent fight and emerging oral obesity challengers highlight just how competitive the metabolic space has become AstraZeneca sets sights on 25+ blockbusters by 2030 to fuel $80B revenue ambitionAstraZeneca board
- Cafepharma - Home | pharma sales, device sales, lab sales | Cafepharma
Biopharma headlines today highlight funding declines, AI’s growing role in drug development and a mix of clinical wins and setbacks across obesity, oncology and neurodegenerative disease Novo Nordisk's strategic U S expansion with new board appointment Novo Nordisk board As Boehringer touts US launches, board chairman worries EU is 'falling further behind' Boehringer Ingelheim board
|
|
|